Findings
========

Introduction
------------

Lipoprotein lipase (LPL), hepatic lipase (HL) and endothelial lipase (EL) are extracellular lipases involved in plasma lipid homeostasis \[[@B1]\]. The secretion and activity of these lipases depends on their post-translational maturation within the endoplasmic reticulum (ER) of lipase-expressing cells \[[@B2]\]. The maturation of lipases involves folding and assembly of nascent polypeptides into catalytically active homodimers, a hallmark structural feature shared among LPL, HL and EL \[[@B3]\]. We have previously demonstrated that lipase maturation factor 1 (LMF1), an ER membrane protein, plays a critical role in lipase maturation \[[@B4],[@B5]\]. In the absence of LMF1, lipases fail to mature into active enzymes, are retained within the ER and undergo intracellular degradation \[[@B3]\]. Highlighting the critical role of LMF1 in lipase expression and lipid metabolism, patients with homozygous LMF1 mutations exhibit plasma lipase deficiency and hypertriglyceridemia \[[@B5]-[@B7]\].

LMF1 was initially identified as the gene disrupted by '*combined lipase deficiency'* (*cld*), a naturally occurring mutation in the mouse \[[@B5]\]. Homozygous *cld* mutant mice exhibit deficiency in plasma LPL and HL activity, develop hyperchylomicronemia and die within a few days after birth likely due to circulatory problems \[[@B8]\]. While the *cld* mouse model has proven valuable for the identification of LMF1, it has several limitations. First, owing to the presence of a recessive lethal mutation (T, brachyury) *in trans* to the *cld* allele, "wild-type" (+/+) progeny obtained from *cld*/+breeders are not viable, which precludes the use of +/+littermate controls in phenotypic analysis \[[@B9]\]. Second, the *cld* mutation arose on an outbred genetic background harboring a variant form of chromosome 17, known as the *t*-haplotype, which is enriched in deleterious mutations affecting several nearby genes \[[@B9]\]. Consequently, phenotypes observed in *cld* mice cannot be unequivocally ascribed to LMF1 deficiency. Finally, the *cld* allele produces a truncated form of LMF1 (LMF1^cld^) corresponding to \~60% of the full-length protein. As LMF1^cld^ is stable and correctly localizes to the ER membrane, *cld* may represent a hypomorphic allele \[[@B4]\]. In conclusion, characterization of the full phenotypic spectrum of LMF1-deficiency requires the generation of mice with a null-allele of LMF1 on an inbred genetic background.

The present study was triggered by the unexpected observation of widespread LMF1 expression in the developing mouse embryo. This observation raised the possibility that LMF1 may be required for embryonic viability, which may not be apparent in the hypomorphic *cld* model. To test this hypothesis, we generated and characterized a novel mouse model of complete LMF1 deficiency. Our results demonstrate that whereas LMF1 is dispensable for the viability of mouse embryo, LMF1 deficiency is associated with lipase deficiency, hypertriglyceridemia and neonatal lethality. The mouse model developed in this study will facilitate the further characterization of LMF1 in development and metabolic regulation.

Methods
=======

Animals
-------

LMF1-deficient mice were generated from a gene-trapped 129/SvEvBrd Omnibank ES cell clone (OST195742) at the Texas A&M Institute for Genomic Medicine \[[@B10]\]. The trapped allele (referred to as 'LMF1-' from here on) was transferred to the C57BL/6J background by backcrossing (N4). Primers used for genotyping (wild-type allele: TG0048-5' and TG0048-3'; gene-trap allele: LTR2 and KO-A) are listed in Table [1](#T1){ref-type="table"}. Mice were maintained on standard laboratory chow (LabDiet 5001) in a specific pathogen-free facility under 14:10 hour light cycle. All animal studies were approved by the Institutional Animal Care and Use Committee at Cedars-Sinai Medical Center.

###### 

Primer sequences

    **Name**                     **Sequence**                    **Application**
  ------------ ------------------------------------------------ -----------------
   TG0048-3\'              AGGCTAAGACTCTTTAGGCTCAGG                Genotyping
   TG0048-5\'             GGCGAGACGATGCTAATTCTATTCC                Genotyping
      LTR2                AAATGGCGTTACTTAAGCTAGCTTGC               Genotyping
      KO-A                  CCGCTTTTCCTGAAGTGAAGGA                 Genotyping
    T7-LMF1     GCCAGTAATACGACTCACTATAGGGATGCGCCCAGACAGCCTAGTA         IVT
    T3-LMF1       GCCAGAATTAACCCTCACTAAAGGGATCTGCAGCACTCCAT            IVT
       p1                    ATGCGCCCAGACAGCCTAGT                    RT-PCR
       p2                   GAGAACCTGCGTGCAATCCAT                    RT-PCR
       p3                     CCCAGAGGGCAGTCATGA                     RT-PCR
       p4                     GGGCATCTCGTCCTTTGT                     RT-PCR
       p5                     GTGACCTGTGCAGGTAGT                     RT-PCR
       p6                    CGTGGAGCTTCTTGTGCCT                      qPCR
       p7                     GGATCTGCAGCACTCCAT                      qPCR
     36B4-f                 CACTGGTCTAGGACCCGAGAAG                    qPCR
     36B4-r                  GGTGCCTCTGGAGATTTTCG                     qPCR

RNA analysis
------------

*In situ* hybridization was carried out by Phylogeny Inc. as described \[[@B11]\]. ^35^S-UTP-labeled sense and anti-sense cRNA probes were generated by *in vitro* transcription (Ambion) from a T7 and T3 promoter-appended PCR product (primers T7-LMF1 and T3-LMF1 in Table [1](#T1){ref-type="table"}) representing the 5'-terminal 889 bp of the LMF1 open reading frame. RNA and cDNA from adult tissues was prepared as described previously \[[@B12]\] and cDNA from embryonic tissues was obtained from OriGene (TissueScan, MDRT). Real-time PCR was performed using LMF1 (\#4351372, Life Technologies) and GAPDH (\#4352339E) TaqMan assays (Figure [1](#F1){ref-type="fig"}B), or SybrGreen assays using primers for LMF1 (p6 and p7 in Table [1](#T1){ref-type="table"}) and 36B4. For semi-quantitative RT-PCR analysis of the gene-trapped LMF1 allele, primers (p1-p5 in Table [1](#T1){ref-type="table"}) spanning multiple exons were used as shown in Figure [2](#F2){ref-type="fig"}A.

![**LMF1 expression in the mouse embryo. (A)***In situ* hybridization of embryo sections with probes representing anti-sense (middle panels) and sense (bottom panels) transcripts of LMF1 at different days *post coitus*. The top panels show bright-field images of cresyl violet-stained sections. Ad, adrenal; Br, brain; Fb, forebrain; H, heart primordium; He, heart; In, intestine; K, kidney; Li, liver; Lu, lung; M, mandibular component of branchial arch; MO, medulla oblongata; SC, spinal cord; Sm, skeletal muscle; T, tail; To, tooth primordium; Ve, vertebrae. **(B)** Real-time PCR analysis of relative LMF1 expression in embryonic and adult tissues.](1743-7075-11-37-1){#F1}

![**Generation of LMF1-/- mice. (A)** Schematic illustration of the novel LMF1 allele showing a gene-trap insertion event in intron 1. Gray numbered boxes represent exons. The gene-trap cassette contains a splice acceptor sequence (SA), neomycin resistance gene (neo) and polyadenylation sequence (pA). Arrowheads indicate primers (p1-p5) used for RT-PCR analysis. **(B)** RT-PCR analysis of LMF1 expression in neonatal liver RNA. **(C)** qPCR analysis of LMF1 expression in mouse embryonic fibroblasts using primers p6 and p7 shown in panel A.](1743-7075-11-37-2){#F2}

Plasma assays
-------------

To obtain post-heparin plasma from newborn mice, pups were injected intraperitoneally with 10 units of heparin followed by decapitation and blood collection 20 minutes later. Blood was centrifuged (4,500 × g for 5 min) in heparinized separation tubes and plasma was used to determine lipid levels, and enzymatic activities of LPL and HL as described \[[@B12]\]. For the assessment of plasma lipoprotein distribution, plasma obtained from 1-day-old pups was pooled and analyzed by FPLC at the Mouse Metabolic Phenotyping Center at Vanderbilt University School of Medicine. Because of high triglyceride content and viscosity, plasma samples from LMF1-/- animals were diluted 30-fold before FPLC analysis. At this dilution, cholesterol concentrations in fractions could not be reliably determined.

Data analysis
-------------

Results are shown as means ± S.E. Statistical analyses were performed with the SigmaStat software. Two-tailed unpaired Student's t-test was used to compare means, and chi-square test was applied for the analysis of genotype frequencies. A p-value \<0.05 was considered statistically significant.

Results
=======

LMF1 expression in the developing mouse embryo
----------------------------------------------

Previous studies indicated that LMF1 was ubiquitously expressed in adult mouse tissues \[[@B5]\]. To investigate whether the broad expression pattern of LMF1 extends to embryonic tissues, we performed *in situ* hybridization studies in the mouse embryo at different stages of development (Figure [1](#F1){ref-type="fig"}A). In E9.5 mid-gestation embryos, strong LMF1 expression was detected in rudiments of the central nervous system, whereas lower mRNA levels were observed in other tissues. LMF1 exhibited ubiquitous expression pattern in E12.5 and E15.5 embryos with elevated levels in skeletal muscles, cartilage of vertebrae and intestine at late-gestation. To characterize LMF1 expression in the developing CNS further, we performed quantitative RT-PCR analysis on RNA isolated from distinct anatomical regions (Figure [1](#F1){ref-type="fig"}B). LMF1 showed uniform and ubiquitous expression in all regions and developmental stages tested. Furthermore, LMF1 mRNA levels were comparable to those in principal lipase-expressing adult tissues including adipose, heart and liver (Figure [1](#F1){ref-type="fig"}B).

Generation of LMF1-deficient mice
---------------------------------

To explore the role of LMF1 in embryonic viability, we generated LMF1-deficient mice using an ES cell clone from a gene-trap library \[[@B10]\]. The targeted allele harbors a gene-trap cassette inserted within the first intron of the LMF1 gene and is predicted to produce a truncated transcript containing exon 1 (Figure [1](#F1){ref-type="fig"}A). Indeed, transcripts corresponding to exon 1 and the gene-trap cassette were readily detectable in mice carrying the mutant allele (Figure [1](#F1){ref-type="fig"}B, middle panel). Importantly, sequences 3' of exon 1 were undetectable in LMF1-/- mice (Figure [1](#F1){ref-type="fig"}B, top and bottom panels). Moreover, expression of exon 6 could not be detected in LMF1-/- mouse embryonic fibroblasts by qPCR, which confirms the absence of LMF1 transcripts with sequences downstream of the gene-trap integration site (Figure [1](#F1){ref-type="fig"}C). As exon 1 encodes the N-terminal 64 residues of LMF1, which lacks membrane-spanning domains and corresponds to \~10% of the full-length polypeptide, we conclude that the gene-trap allele most likely represents a null-allele of LMF1.

Characterization of LMF1-deficient mice
---------------------------------------

To investigate the impact of LMF1 deficiency on embryonic viability, we genotyped offspring obtained from heterozygous LMF1+/- matings. On the first day after birth, the LMF1-/- genotype was represented at a Mendelian ratio (i.e. 25%) among littermates indicating that LMF1 was dispensable for embryonic viability (Figure [3](#F3){ref-type="fig"}A). However, the proportion of LMF1-/- pups gradually decreased in subsequent days and no surviving LMF1-deficient progeny could be identified 4 days after birth (Figure [3](#F3){ref-type="fig"}A).

![**Characterization of LMF1-/- mice. (A)** Survival of LMF1-deficient (LMF1-/-) progeny during days 1 to 4 (d1 to d4) after birth. Dashed line indicates Mendelian frequency (25%) of -/- genotype as expected from heterozygous matings. White numbers show total number of pups genotyped at each time-point. Asterisks indicate significant (p \< 0.05) differences from expected genotype frequencies (χ^2^ test). **(B)** White fat-cake indicates hyperlipidemia in plasma of -/- neonates. **(C)** Plasma triglyceride (TG), **(D)** total cholesterol (TC), and **(E)** HDL-cholesterol (HDL-C) levels are shown in newborn mice. **(F)** Plasma triglyceride and **(G)** cholesterol profiles were determined by FPLC analysis. **(H)** Post-heparin LPL and **(I)** HL activities in newborn mice. \*, p \< 0.05.](1743-7075-11-37-3){#F3}

To assess metabolic manifestations of LMF1 deficiency in the LMF1-/- model, we characterized newborn mice within the first day of life. LMF1-deficient neonates did not exhibit apparent morphological defects. However, their plasma had a milky appearance (Figure [3](#F3){ref-type="fig"}B), a consequence of \~80-fold elevated triglyceride concentration relative to unaffected littermates (Figure [3](#F3){ref-type="fig"}C). Hypertriglyceridemia in LMF1-/- pups was due to combined lipase deficiency as demonstrated by dramatically reduced post-heparin LPL and HL activities (Figure [3](#F3){ref-type="fig"}H and I). As expected, triglycerides were overwhelmingly associated with the chylomicron/VLDL fraction in LMF1-/- plasma (Figure [3](#F3){ref-type="fig"}F). Relative to wild-type and heterozygous littermates, LMF1-/- mice also demonstrated elevated total cholesterol (Figure [3](#F3){ref-type="fig"}D), but similar HDL-cholesterol levels (Figure [3](#F3){ref-type="fig"}E). We were unable to directly assess the cholesterol profile in LMF1-/- mice, because severe lipemia and high viscosity necessitated dilutions of samples before FPLC analysis to an extent, which prevented the detection of cholesterol in fractions. Nonetheless, wild-type and heterozygous mice exhibited similar plasma cholesterol distribution (Figure [3](#F3){ref-type="fig"}G), where cholesterol was predominantly associated with IDL/LDL particles, a characteristic feature of fetal murine lipoprotein profile \[[@B13]\].

Discussion
==========

In the present study, we generated a novel mouse model of LMF1 deficiency using gene-trap mutagenesis. The new model offers advantages over the naturally occurring *cld* mutant mouse strain used in previous studies \[[@B5],[@B8]\]. First, in contrast to a truncating mutation in the *cld* model, the gene-trap insertion characterized here represents a definitive null-allele and allows analysis of the full phenotypic manifestation of LMF1 deficiency. An additional improvement of the new model over *cld* is that wild-type littermates are viable, which enables characterization of the potential phenotypic consequences of heterozygous LMF1 deficiency. Finally, the gene-trap allele is on an inbred genetic background devoid of the confounding genetic effects associated with the *cld* mutation \[[@B9]\].

We unexpectedly detected ubiquitous and relatively high-level LMF1 expression in the mouse embryo. This observation raised the possibility that in addition to its established role in postnatal lipid metabolism, LMF1 may also be an important factor in embryogenesis. While the role of vascular lipases during development remains poorly characterized, embryonic expression of all three LMF1-dependent lipases (i.e. LPL, HL and EL) has previously been documented \[[@B14],[@B15]\]. To begin to address the potential role of LMF1 in development, we first asked whether LMF1 deficiency affects the viability of embryos. Our results demonstrate that despite widespread expression in the developing embryo, LMF1 is not required for embryonic survival. However, postnatal viability of LMF1-/- pups is severely compromised, as no surviving LMF1-deficient progeny was detected a few days after birth. Neonatal lethality has also been observed in *cld* mice \[[@B8]\] and is thought to be a consequence of circulatory problems associated with severe hyperchylomicronemia, which results from the inability to utilize dietary fat during suckling \[[@B16]\]. Indeed, LMF1-/- pups exhibit hypertriglyceridemia and severely diminished post-heparin LPL and HL activities, hallmark features of LMF1 deficiency in the *cld* mouse model \[[@B8]\]. In addition to hypertriglyceridemia, plasma concentrations of total cholesterol are also elevated in LMF1-/- mice, a likely consequence of diminished catabolism and accumulation of chylomicron particles due to LPL deficiency \[[@B17]\]. In contrast to total cholesterol, HDL-cholesterol levels are unaffected in LMF1-/- plasma. At first glance, this is a surprising observation considering the critical role of LPL in the maturation of HDL particles \[[@B18]\] and severely reduced HDL-cholesterol in LPL-deficient mice \[[@B17],[@B19],[@B20]\]. However, in addition to LPL, LMF1-/- animals are also deficient in active HL and EL \[[@B7]\], lipases that promote HDL catabolism \[[@B21]-[@B23]\]. Thus, we propose that unaltered HDL-cholesterol level in LMF1-/- mice is a result of combined lipase deficiency involving lipases with opposite effects on HDL metabolism.

LMF1-deficient mice developed in this work will allow in-depth investigations of the role of LMF1 in development. However, early lethality is a limitation of this model for metabolic studies in the adult organism. Neonatal lethality in LMF1-/- mice is not unique among mouse models of hypertriglyceridemia. LPL-deficient mice die within a few days after birth, most likely as a consequence of restricted oxygen exchange in lipid-engorged lung capillaries \[[@B17]\]. In contrast, hypertriglyceridemia in mice deficient in GPIHBP1, a protein involved in the trans-endothelial transport of LPL, is not associated with increased mortality owing to the availability of a functional pool of LPL in the neonatal liver \[[@B24],[@B25]\]. Two strategies have been used to rescue LPL-deficient mice from neonatal lethality. First, transient expression of LPL through adenoviral gene transfer allowed a small fraction of infected LPL-/- progeny to reach adulthood and enabled metabolic characterization of LPL-deficiency \[[@B18],[@B20],[@B26]\]. We attempted a similar strategy to rescue LMF1-/- pups using adenovirus expressing LMF1, but have been unable to recover adult LMF1-deficient mice (unpublished observation). Importantly, LMF1-deficient mice are not only devoid of active LPL, but also HL and EL, which may result in more severe morbidity relative to LPL-deficiency only and explain why transient expression of LMF1 is insufficient for rescue. Consistent with this explanation, HL/EL double knock-out mice suffer from neonatal lethality \[[@B23]\], which raises the possibility that combined HL/EL-deficiency contributes to mortality in LMF1-/- mice. A second strategy that has been successfully applied to rescue LPL-/- mice is based on transgenic complementation of LPL expression in single tissues such as heart, skeletal muscle and liver \[[@B27]-[@B29]\]. A similar approach is currently pursued in our laboratory to rescue LMF1-/- mice using a muscle-specific LMF1 transgene \[[@B12]\].

In conclusion, we validated a new LMF1-deficient mouse model by demonstrating that it recapitulates salient phenotypes of *cld* mutant mice including neonatal lethality, dyslipidemia and combined lipase deficiency. At the same time, our study also confirms that phenotypes previously observed in the *cld* model are genuine consequences of LMF1 deficiency, as opposed to unrelated mutations present in the *cld* genetic background \[[@B9]\]. The fact that our initial characterization of LMF1-/- neonates did not reveal novel phenotypes beyond those already observed in *cld* mice is consistent with the possibility that *cld* represents a null-allele of LMF1. However, more detailed phenotypic characterization will be necessary before a definitive conclusion can be reached. The LMF1-deficient mouse model developed in this study will facilitate further analysis of LMF1 function in development and metabolic regulation.
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